Cohort Year: 2026

Vitalic

Vitalic is a geriatric-specialized and team-based behavioral health practice that uniquely provides the proactive outreach and engagement required to enroll and treat the often reluctant 65+members into behavioral health care that is proven to improve clinical outcomes while reducing total cost of care.

Year
Status
Entry Stage
Current Stage

SocialRx

SocialRx (formerly known as Art Pharmacy) is a leading social prescribing platform that helps health plans, employers, and universities tackle the growing crisis of loneliness and mental health through arts, culture, and nature. By combining technology, human-centered care navigation, and evidence-based models, SocialRx transforms community connection into measurable improvements in mental well-being and belonging across the United States.

Year
Status
Entry Stage
Current Stage

Radicle Science

Radicle Science is a healthtech public benefit corporation on a mission to transform the $1T global wellness industry by enabling rigorous science at unprecedented speed, scale, and precision. By fusing AI, consumer science, and massively scalable real world clinical trials, Radicle is enabling a new generation of proven, precision nonprescription treatments–accessible to all.

Year
Status
Entry Stage
Current Stage

Orbit

Orbit is building foundation models of cognitive states and conditions, enabling precision mental healthcare. They are collecting unprecedentedly rich neural data-sets, enabled by their novel brain wearable which can achieve fMRI-comparable resolution at scale.

Year
Status
Entry Stage
Current Stage

Nosis Health

Nosis is building a new model for substance use care – one focused on building health and vitality, not just stopping use. By combining addiction medicine, advanced diagnostics, therapy, coaching, and lifestyle interventions, we help people heal their brains, rebuild their bodies, and create the conditions for lasting wellbeing.

Year
Status
Entry Stage
Current Stage

Neurofundus

Engram (formerly Neurofundus) is building foundation models for precision psychiatry. By comprehensively mapping the phenotype and biology of disease subtypes, we will enable personalized treatment trajectories and precision drug discovery. To this end, we are collaborating with hospitals internationally to collect and generate multimodal data on thousands of patients, starting with depression.

Year
Status
Entry Stage
Current Stage

Monument Therapeutics

Monument Tx is a neuroscience-focused drug development company using digital biomarkers to develop more targeted treatments for psychiatric and neurological disorders. Lead program MT1988 is currently in a large patient study in clinical high risk for psychosis individuals to assess its potential to improve cognitive impairment associated with schizophrenia and validate its predictive digital biomarker.

Year
Status
Entry Stage
Current Stage

manatee

Manatee is a family mental health provider addressing the pediatric mental health crisis by treating the entire family system, including parents. Their evidence-based, whole-family model is proven to be 4x more engaging and 3x more effective than traditional, child-only therapy.

Year
Status
Entry Stage
Current Stage

Limbic

Limbic is a clinically-validated AI agent for mental healthcare, used by health systems and payers across the UK and US. The AI has supported more than 600,000 patients in treatment, and is the only AI mental health chatbot approved as a Class II medical device, supported by a growing evidence base of seven peer-reviewed studies, including in Nature Medicine.

Year
Status
Entry Stage
Current Stage

Forecast Bio

Forecast Bio is building an AI-powered preclinical platform that directly links complex cellular neurobiology to patients’ mental health outcomes. By mapping how new drugs impact human brain circuits and symptoms, Forecast is speeding up therapeutics development by 10x—and radically transforming what’s possible in brain and mind health.

Year
Status
Entry Stage
Current Stage

Flow Neuroscience

Flow Neuroscience is pioneering a new category of at-home electric medicine and delivering drug-free, brain-based treatments for mental health. Flow is world’s first clinically validated FDA approved at-home transcranial direct current stimulation (tDCS) headset. Since its European launch in 2019, Flow has become the only CE-marked at-home tDCS treatment for depression used by the NHS, empowering more than 55,000 people to take control of their mental health. With FDA approval in 2025, the US joins the UAE, Australia, Brazil, the UK and EU as countries where Flow’s accessible depression treatment is available.

Year
Status
Entry Stage
Current Stage

Eratos Therapeutics

Eratos Therapeutics is revolutionizing CNS drug discovery with its groundbreaking approach, integrating spatial computing and AI-driven nanoscale mapping to build ground-truth world models of the brain. By leveraging advanced technologies, Eratos identifies high-specificity therapeutic targets and expedites the development of precision-engineered therapeutics for neurodegenerative, neuroinflammatory, and neuropsychiatric disorders.

Year
Status
Entry Stage
Current Stage